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The health and management of poultry production 
Charles L. Hofacre (I) 
The poultry industry in the USA is a fully integrated system of animal agriculture. Each company has control over 
the bird husbandry and health management aspects of production, including the use of antimicrobial agents. The 
three segments of the industry-broiler chickens, turkeys, and layer chickens-have few antibiotics available for the 
therapeutic treatment of bacterial diseases. Prior to approval of the fluoroquinolones, tetracyclines were the major 
antibiotics approved for the treatment of the most economically important disease in broiler chickens and turkeys, 
Escherichia coli airsacculitis. This resulted in levels of resistance to the tetracyclines in clinical E. coli isolates in excess 
of 90%. The integrated nature of the poultry industry lends itself well to preventive medicine utilizing the tools of 
biosecurity and vaccination. Therefore, very few flocks of birds require antibiotic therapy. When a flock must be 
treated, the poultry veterinarian will usually base the recommendation of the drug to use on culture and antibiogram 
results. 
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The poultry industry in the USA is a fully integrated 
system of animal agriculture. Each poultry company has 
control over all fiscal and bird husbandry aspects of 
production, from the day-old parent breeders to the 
marketing and distribution of the final products to the 
retailer. The ‘poultry industry’ is actually three different 
industries, commercial layers, broilers, and turkeys. 
Commercial layers are chickens of the leghorn breed 
that lay table eggs for human consumption. There are 
approximately 275 million table egg layers in production 
in the USA.l When these birds begin laying eggs for 
human consumption at 18-19 weeks of age, they can 
only be treated with a small number of antibiotics that 
have been demonstrated to result in no antibiotic residue 
in the eggs.2,3 
The US turkey (272 million) and broiler chicken 
(8.5 billion) industries are similar to each other, with the 
company purchasing the parent breeders at 1 day of 
age or hatching eggs from a primary breeder or genetic 
selection c0mpany.l These birds are raised on farms 
contracted by the company under specific company 
guidelines for antibiotic usage. The offspring (broiler 
chickens or commercial turkeys) of these breeders are 
hatched in company-owned hatcheries, and placed on a 
contract or company-owned farm, where the farmer 
must follow strict company guidelines for antibiotic 
usage. All feed that is fed to the breeders, broiler 
chickens or commercial turkeys is manufactured in a 
company-owned feedmill under specific guidelines of 
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a company. The company nutritionist will specify the 
nutritional aspects of the feed, and the veterinarian will 
determine any antibiotic usage requirements. The birds 
will then be slaughtered in a company-owned processing 
plant. 
The typical US broiler chicken farm will have 
approximately 100 000 chickens, divided equally into 
four houses. As in a city of 100 000 people, disease 
prevention becomes imperative for the poultry industry. 
Poultry veterinarians practice preventive medicine, utiliz- 
ing two primary tools, biosecurity and vaccination. The 
US average level of death loss (mortality) in the typical 
100 OOO-bird broiler farm is 4-5%.4 There is also loss 
of approximately 0.5-1.0% of the birds for human 
consumption in the processing plant, when birds are 
removed by the United States Department of Agri- 
culture-Food Safety Inspection Service (USDA-FSIS) 
inspectors, primarily for visible signs of respiratory 
disease, most often due to an Escherichia coli infection.4 
In those cases where a disease has been introduced 
onto a farm, the poultry veterinarian must decide whether 
the birds can be treated with an antibiotic, and, if so, 
which antibiotic and by what route of administration (in 
feed or drinking water). The choice of antibiotic is often 
limited by the cost of the drug versus level of disease, 
and also by the safe duration of withdrawal prior to 
slaughter to ensure that no drug residue is found in the 
meat. The vast majority of therapeutic treatments are 
given via the drinking water, because sick birds stop 
eating, but continue to consume water. As for layer 
chickens, the choice of antibiotics available to poultry 
veterinarians for the treatment of bacterial infections 
is limited (Table 1). Until the fluoroquinolones were 
approved for poultry, the primary antibiotic class avail- 
able for E. coli infections comprised the tetracyclines. 
This limited choice of antibiotic therapy has led to a 
level of tetracycline resistance in poultry E. co/i isolates 
exceeding 90% .5 
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Table 1. Therapeutic antibiotics for poultry2*3 
Antibiotic 
Egg-layer chickens Broiler chickens 
Drinking Drinking 
Feed water Feed water 
Turkeys 
Drinking 
Feed water 
Bacitracin 
Chlortetracycline 
Erythromycin 
Enrofloxacin 
Lincomycin 
Neomycin 
Novobiocin 
Oxytetracycline 
Penicillin 
Streptomycin 
Sulfadimethoxine 
and ormetroprim 
Tylosin 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Yes 
Yes 
Yes 
No 
Yes 
No 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
No 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
No 
No 
No 
Yes 
Yes 
Yes 
No 
Yes 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
No 
Yes 
No 
Another factor relevant to the choice of antibiotic 
is the cost of the drug. It has been estimated by one 
particular broiler company that the mortality must 
exceed 1000 birds per farm before it is economically 
feasible to use a fluoroquinolone (personal communi- 
cation). This is why fluoroquinolones are infrequently 
used in broilers. Most of the E. coli infections are 
secondary, and result from primary infections caused by 
Newcastle disease virus or infectious bronchitis virus 
(IBV). IBV is a coronavirus that undergoes genomic 
reassortment and homologous recombination in vivo. 
Therefore, over time, new genotypes arise to which 
large populations of birds may be susceptible. Infected, 
medicated flocks may lose uniformity of body weight if 
treatment is unable to restore normal body physiology. 
The issue of antibiotic resistance in potential human 
foodborne pathogens such as Salmonella and Campylo- 
batter also becomes an issue when selecting an anti- 
biotic for treating an E. coli infection in broilers or 
turkeys.The FSIS issued the Pathogen Reduction; Hazard 
Analysis and Critical Control Point (HACCP) Systems 
regulations in 1996; these imposed on all poultry-pro- 
cessing plants a system of performance standards for 
Salmonella with regard to the final product.6 The results 
of this program have shown continued improvements in 
pathogen reduction by the broiler industry. Additionally, 
this began to raise the awareness of consumers about 
Salmonella and other foodborne pathogens that could 
be resistant to antibiotics used to treat human infections. 
Therefore, many food markets and restaurants began to 
require that the poultry products originate from farms 
with no history of usage of specific antibiotics such as the 
fluoroquinolones. 
The fully integrated nature of the poultry industry 
allows the poultry-producing company to implement 
bird husbandry practices that impact on a large pro- 
portion of the meat supply for the US consumer. It is 
therefore imperative that preventive health programs as 
well as appropriate therapeutic strategies are practiced 
to avoid not only disease in the birds, but also pre- 
vention of introduction of potential human foodborne 
pathogens. This means that, when birds must be treated 
with antibiotics, not only effectiveness against the disease- 
causing bacteria, but also the impact on foodborne 
pathogens, must enter into the decision-making process 
of the poultry veterinarian.The ever-increasing pressure 
on food retailers by consumers to limit the use of anti- 
biotics in food-producing animals limits the choices 
for therapy by poultry veterinarians and the means by 
which they can ensure that healthy birds can be brought 
to processing. 
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PANEL DISCUSSION 
M. Ginevan: In your example of birds at 1 week to 
slaughter, could a third possible choice of handling that 
illness in that house be to send the birds in that house to 
slaughter early, not treat them, and confine your losses 
to that? 
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C. Hofacre: If you can. It depends on the marketing of 
the birds for that company-the sales department for 
the company. If you are selling a product of a smaller 
bird and a bird of 49 days, then you might be able to 
switch and process another farm later, and pull this one 
in earlier. In many instances when it gets that close to 
processing, this is like a very well-oiled machine; if one 
thing breaks down, it really becomes difficult. Every- 
thing starts to pile up behind. 
R. Carnevale: If you were unable to use enrofloxacin 
because it was no longer on the market for this use, what 
antibiotic would you have used in this house? 
C. Hofacre: I would have used tetracyclines, at as high a 
level as I could. Because E. coli is a secondary infection, 
very often in the isolation we will find that 90% of the 
isolates within this outbreak will be resistant, but there 
will be a few that will be sensitive. You will be able to 
slow the course of the disease but you won’t be able to 
stop it. 
C. Thornsberry: What happens if you get back a report 
from the laboratory that says the bacterium is resistant 
to enrofloxacin? 
C. Hofacre: If these were younger birds, say 3 weeks old, 
and we had an airsacculitis outbreak, and the report 
came back that it was resistant to the drug that we were 
using, then we would switch. If the report said that they 
were sensitive to the sulfas, then we might use one of the 
potentiated sulfas on a younger group of birds. On birds 
this close to slaughter, your options are limited. By the 
time you get the report, they are probably on the way to 
market. 
C. Thornsberry: Do you really bother to re-treat? 
C. Hofacre: No. For these birds in particular, you wouldn’t 
have enough time. 
E . Gonder: You might give them some idea of the rather 
tight weight ranges they are faced with in broiler 
processing. In the turkey industry, we would be more 
likely to try to ship a flock early, because we have some 
leeway on sizes. Mostly, the broiler industry, particularly 
if the birds are intended for a particular market, wants 
the weight in that flock to be within r/b of a pound, so the 
options begin to drop fairly quickly on getting the bird 
into the plant. Those of you who aren’t familiar with 
the poultry business may not realize how quickly the 
growth rate changes in these animals. I just did a brief 
calculation here, one that my major professor did some 
years ago; but in the turkey industry in particular, you 
start with a 50-g poult, and at the end of 20 weeks you 
have an 18-kg market turkey. If you translate that into 
human terms, it means that if you have a 7-pound baby, 
at the end of 20 weeks he weighs 2520 pounds. We are 
acutely interested in maintaining that growth rate. That 
is where we make our money. That is one of the reasons 
why preventive medicine is so important to us. 
C. Hofacre: We view disease as a failure. Treatment is a 
salvage option. 
G. Tillotson: You demonstrated the economic signi- 
ficance of resorting to enrofloxacin, so, the cost and legal 
implications notwithstanding, I suppose that nobody would 
consider using a Auoroquinolone as a preventative, as 
prophylaxis, from the outset. 
C. Hofacre: There is nobody in the USA who has, as 
far as I know, used fluoroquinolones in a prophylactic 
way. 
Comment: You emphasized the importance of this E. coli 
infection being secondary to something else. Unless I 
missed it, you didn’t carry on with your case study and 
tell us what you might have found and what you would 
do if you found evidence of a virus infection. Can you 
elaborate on that? 
C. Hofacre: If it is an infectious bronchitis or a 
Newcastle virus-in most instances in broilers, it will be 
an infectious bronchitis-we will try to find out which 
serotype of infectious bronchitis it is (most commonly it 
will be a corona virus) and where it came from; if it 
is not part of our vaccination program, then we may 
decide to add that serotype to the vaccination program. 
The indication of a different serotype would come from 
serology, but confirmation will come with virus isolation 
and then determining through an RT-PCR which sero- 
type of infectious bronchitis virus we are dealing with. 
If there is a vaccine available for that type, a commercial 
vaccine, then we use that the next time on that farm. 
Question: How often does the event you describe occur 
in an area over a given time period? Is it an isolated event 
or does it happen every day? 
C. Hofacre: When we talk about an area for a broiler 
industry, we are talking about what is termed a complex. 
A complex is a self-contained unit within an area. For 
example, a large complex in Athens, Georgia has a 
feedmill, a hatchery, broiler farms, breeder farms and 
all the personnel to go along with that in a processing 
plant.That complex places about 1.5 million broilers per 
week. Within that 1.5 million, there will probably be one 
or two farms per week that will have this airsacculitis 
problem, because it is fairly difficult with a high popu- 
lation density not to have these viruses circulating about. 
It is probably less than l-2%, which would be an easier 
way to look at it. One of the things that I didn’t show you 
in the table of poultry numbers from the economics is 
that 96% is the average proportion of birds that survive 
to go to the processing plant. Not a lot of birds die 
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during the growing period, and most of those that do die, 
do so as a result of physiologic or leg problems or other 
management issues, rather than from disease. 
E. Gonder: One other thing that you might point out 
would be the effect a flock like that would have on 
the septicemia-toxemia condemnation figures. This is 
relevant to the question about incidence, because any of 
the birds that enter the processing plant with extensive 
fibrinous airsacculitis are going to be condemned, 
probably falling into either the septicemia-toxemia or 
airsacculitis categories. That brings us back to the figures 
shown on the national incidence of septicemia-toxemia 
and airsacculitis condemnations. 
M. Pasternack: I have a couple of questions about E. coli 
infection. Is that a particular strain of E. coli, or is this a 
common bug in your average chicken house? 
C. Hofacre: Most of the time it is normal floral E. coli 
that are opportunistic: 01, 02 and 078 are the most 
common serotypes. There are pathogenic E. coli sero- 
types that are found everywhere in the intestinal track, 
just as normal flora. 
E. Rubinstein: Do you think that it is feasible to develop 
a vaccine to protect chickens from E. cob infections? 
C. Hofacre: There has been some work with some live 
vaccines, but because the bacteria are opportunists and 
there are so many E. coli serotypes, you may vaccinate 
against one type, but others will take their place. 
C. Thornsberry: Has the rate of quinolone resistance 
among the E. cob isolates risen over the time frame that 
enrofloxacin has been available? 
C. Hofacre: Yes. There has been, as with the introduction 
of any antibiotic, the selection of resistant bacteria. We 
saw virtually no fluoroquinolone-resistant E. coli isolates 
in the USA to begin with, but, with use, we have started 
to see a few. 
Question: What happens to the birds if you have an 
outbreak and they die? What do you do with the car- 
casses? 
C. Hofacre: There are various methods of disposal used 
in the USA. There is burial. There is incineration. Those 
would probably be the two most common. There is also 
composting, where the carcasses are mixed in with used 
bedding material, allowing heat and decomposition 
within that bin. 
C. Thornsberry: I would like to go back to the resistant 
E. cob. In my experience and opinion, the resistance of 
E. coli to fluoroquinolones is not a problem. In human 
medicine, in this country alone, we use over $2 billion 
worth. I know we don’t measure antibiotics in dollars, 
but $2 billion is a lot of fluoroquinolones; the amount of 
resistance that we see in E. coli is somewhere in the 
neighborhood of 24%) and doesn’t change much. What 
you have in your situation, if you are looking at one 
house, is an infection control problem, not a measure- 
ment of the amount of resistance you are likely to see in 
E. coli. 
C. Hofacre: You are correct in that we are selecting for 
a population of bacteria. We are not inducing resistance, 
but selecting for bacteria that are resistant. There are 
almost no treatment failures. I don’t know of anyone 
who has mentioned a treatment failure with a fluoro- 
quinolone for an airsacculitis infection in chickens or in 
turkeys. 
D. Newell: Would.your clinical decision be influenced 
at all if you were aware that the flock was positive or 
negative for Campylobacter? 
C. Hofacre: I wouldn’t have prior knowledge, but no. We 
really don’t understand enough about Campylobacter. 
In my opinion, the actual epidemiology or ecology of 
Campylobacter in the poultry industry is not well 
enough understood for me to say that if I treated with 
this I am going to have some sort of problem at the 
processing plant with resistant Campylobacter in the 
birds. 
T. Wassenaar: Are you going to refer to the incidence of 
CampyZobacter in poultry and what the different species 
are in the different species of birds? 
C. Hofacre: Campylobacter jejuni is the primary species 
in broilers, and C. coli is the primary one in turkeys. The 
incidence of both is quite high. We are probably looking 
at 80-90% of the birds having Campylobacter when they 
are processed. 
Question: Would you expect any impact on processing, 
other than the live weight disparities, to occur if you chose 
not to treat that flock? 
C. Hofacre: If we chose not to treat that flock, a lot of 
the birds would have fibrinous pericarditis, and the Food 
Safety Inspection Service would condemn them. I don’t 
know if it has ever been clinically demonstrated or 
published, but one of the things that we have noticed 
is that broiler flocks that have had airsacculitis and have 
higher airsacculitis or septicemia-toxemia condem- 
nation rates tend to have higher bacterial counts on the 
carcasses as well. If we can cure them or decrease the 
disease incidence, we may actually have a more whole- 
some carcass. 
Question: Would that be mostly re-processed birds? 
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C. Hofacre: Most of those would go into re-processing. C. Hofacre: It helps to break these disease cycles, having 
If the problem is septicemia-toxemia, they won’t be re- all-in, all-out. It allows us to completely clean and dis- 
processed. With airsacculitis, they can be re-processed at infect. We don’t start totally anew, but it helps to mini- 
some plants. mize the impact of any of those bacteria. 
E. Gonder: You didn’t mention the effect that the all-in, 
all-out production method used in the poultry industry 
has on antimicrobial-resistant bacteria. This must be 
one of our strengths. 
